ABBOTT LABORATORIES — Director's Dealing 2026

Feb 6, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2026-02-04

Reporting Person: STARKS DANIEL J (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-04	Common shares without par value	P	4967	$109.1388	Acquired	6733784	Direct
2026-02-04	Common shares without par value	P	5033	$108.3328	Acquired	6738817	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	258	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.8150 to $109.5204, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.7700 to $108.7150, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.